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IL-13-Stimulated Human Keratinocytes Preferentially
Attract CD4þCCR4þ T cells: Possible Role in Atopic
Dermatitis
Rahul Purwar1, Thomas Werfel1 and Miriam Wittmann1
Skin inflammation in atopic dermatitis (AD) is characterized by the predominant infiltration of T-helper (Th)2-
cells in lesional skin. However, the mechanism of recruitment of these cells in lesional skin of AD is not yet fully
elucidated. In this study, we investigated the role of IL-13-stimulated human primary keratinocytes (HPKs) in the
recruitment of lymphocytes and further delineated the mechanism of enrichment of these cells. In the
migration assays, we observed preferential enrichment of CD4þCCR4þ T cells towards IL-13-stimulated HPKs.
Interestingly, CD4þCCR4þ T cells from AD showed a higher chemotactic response than those from healthy
individuals. We observed a significant increase in the expression of CCL22 in IL-13-stimulated HPKs as
compared to unstimulated cells. Blocking of CCL22 in IL-13-stimulated HPKs by a neutralizing antibody resulted
in 70–90% inhibition in migration of CD4þCCR4þ T cells. Moreover, IL-13 upregulated IFN-g-induced
chemokines, CCL2 and CCL5, in HPKs. Taken together, our data suggest that IL-13-stimulated HPKs participate
in a positive feedback loop by preferentially enriching Th2-cells in lesional skin of acute AD patients. However,
in chronic phase, IL-13 may act in synergy with IFN-g resulting in lymphocytes recruitment of a mixed phenotype
at the site of inflammation, thus contributing to the chronification of eczema.
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INTRODUCTION
Atopic dermatitis (AD) is a chronic inflammatory skin disease
and characterized particularly by infiltration of lymphocytes
into the skin compartment. Chemokines are potent chemoat-
tractants and activating factors, which play a critical role in
defining the nature of the inflammatory infiltrate in AD (Ono
et al., 2003). In acute skin lesions, accumulation of T-helper
(Th)2-lymphocytes producing IL-4 and/or IL-13 and expres-
sing CCR4 has been observed (Hamid et al., 1996; Nakatani
et al., 2001; Wakugawa et al., 2001). In contrast to a more
Th2-like micromilieu in acute lesions, IFN-g has been
reported to be expressed in chronic skin lesions in AD
(Werfel et al., 1996).
IL-13 is known as a pivotal mediator of Th2 immune
responses (Wynn, 2003). CD4þ T cells and mast cells are
major sources of IL-13 in acute lesions and in peripheral
blood of AD (Obara et al., 2002). Recently, a higher number
of IL-13-expressing CD4þ T cells in peripheral blood
mononuclear cells have been observed in AD patients than
in healthy individuals (La Grutta et al., 2005). Additionally, it
has also been described that, in AD skin lesions, there is a
higher number of IL-13-positive cells in the acute phase than
in the chronic phase (Hamid et al., 1996).
IL-13 does not exert direct effects on T cells, which lack a
functional IL-13 receptor (Zurawski and de Vries, 1994).
Therefore, unlike IL-4, it does not support the proliferation
and differentiation of naive T cells into Th2 phenotype. IL-13
has been described to upregulate the expression of vascular
cell adhesion molecule-1 on endothelial cells (Sironi et al.,
1994) to enhance the expression of various adhesion
molecules on monocytes, such as CD11b, CD11c, CD18,
CD29, and CD49e (VLA-4) (reviewed in de Vries, 1998), and
to upregulate IL-6 (Derocq et al., 1994) as well as IFN-g-
induced CCL5 secretion in keratinocytes (Wongpiyabovorn
et al., 2003).
Originally, Th1 and Th2 subsets have been functionally
separated based on their profiles of cytokine production.
However, it has now become obvious that certain types of
chemokine receptors are selectively expressed on either Th1-
(e.g. CXCR3, CCR5) or Th2-cells (e.g. CCR4, CCR8, CRTH2)
(Bonecchi et al., 1998a; Nagata et al., 1999; Gombert et al.,
2005). In vitro studies have revealed that high-affinity ligands
for CCR4, thymus, activation-regulated chemokine (CCL17),
and macrophage-derived chemokine (CCL22) induce selec-
tive migration of Th2-cells (Imai et al., 1998, 1999).
However, expression of CCR4 has also been documented
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on cutaneous lymphocyte antigen-positive memory T cells
and Th0-cells (Campbell et al., 1999). Recently, the chemo-
attractant receptor-homologous molecule that expressed Th2-
cells (CRTH2) has been shown to be selectively expressed on
Th2-cells (Cosmi et al., 2000).
Expression of CCR4 has been speculated to be important
for T-cell infiltration into skin lesions of AD (Wakugawa
et al., 2001). The frequency of CD4þCCR4þ T cells in
peripheral blood of AD patients has been reported higher
than that of healthy individuals and has been correlated with
severity of the disease (Nakatani et al., 2001). Additionally, in
the epidermal layer of AD skin, keratinocytes have been
shown to be positive for CCL17 and CCL22 (Vestergaard
et al., 2000; Horikawa et al., 2002). Activated human primary
keratinocytes (HPKs) are an important source of chemokines,
hence capable of regulating the progression of the inflam-
matory response. Recently, interaction of T-lymphocytes and
keratinocytes has been shown to promote Th1 cell accumu-
lation in chronic inflammatory skin diseases (Albanesi et al.,
2001; Klunker et al., 2003).
These observations led us to hypothesize that IL-13 plays
an important role in the recruitment of inflammatory cells
to the sites of AD skin lesions. Co-localization of IL-13-
producing CD4þ T cells and keratinocytes expressing IL-13
receptor in the skin of AD patients (Wongpiyabovorn et al.,
2003) prompted us to investigate if IL-13-stimulated HPKs
can attract effector subsets of CD4þ T cells. In this study, we
report that IL-13-stimulated chemokine(s) released by HPKs
preferentially enrich CD4þCCR4þ T cells. Higher chemo-
taxis indices of CD4þCCR4þ T cells from AD patients than
from normal subjects could be observed. In addition, we
have shown that IL-13 alone induces CCL22 and a little but
significant amount of CCL2 in HPKs. Furthermore, IL-13
enhances IFN-g-induced CCL2 and CCL5 in HPKs. Taken
together, these findings suggest that IL-13-stimulated chemo-
kine(s) released by HPKs may play a role in the initiation and
persistence of skin inflammation in AD.
RESULTS
IL-13-stimulated HPKs preferentially attract CD4þCCR4þ T
cells
To determine if IL-13-stimulated HPKs could contribute to the
recruitment of CD4þ T cells, we investigated the migratory
capacity of CD4þ T cells towards IL-13-stimulated HPKs in a
transwell chemotaxis assay. In this direction, we added
purified CD4þ T cells, from healthy individuals, suspended
in keratinocyte growth medium in the upper chamber of a
transwell culture insert containing IL-13-treated or -untreated
HPKs in the lower chamber. After 3 hours of transmigration,
we observed a significant increase in the absolute number of
migrated CD4þ T cells in response to IL-13-stimulated HPKs
as compared to unstimulated controls (P¼0.01; Figure 1a).
We further characterized whether chemokines produced by
IL-13-stimulated HPKs could in turn promote the preferential
migration of Th1-lymphocytes (CD4þCXCR3þ ) versus Th2-
lymphocytes (CD4þCCR4þ ). We used the CXCR3 and CCR4
chemokine receptor to characterize Th1- and Th2-cells.
As depicted in Figure 1a and b, a significantly higher number
of CD4þCCR4þ T cells migrated towards IL-13-stimulated
HPKs than towards unstimulated cells (P¼ 0.002). There was
a basal migration of CD4þCXCR3þ T cells towards
unstimulated and IL-13-stimulated HPKs; however, there
was no significant difference in migration of these cells
towards IL-13-stimulated HPKs than to unstimulated cells
(Figure 1a). In contrast to this, as depicted in Figure 1b,
significantly higher migration of CD4þCXCR3þ T cells
and CD4þCCR4þ T cells was observed in response to
IFN-g-stimulated HPKs as compared to unstimulated cells
(P¼0.01). Chemotaxis index of CD4þCXCR3þ T cells was
higher as than that of CD4þCCR4þT cells in IFN-g-
stimulated HPKs (Figure 1b).
IL-13-stimulated HPKs attract more CD4þCCR4þ T cells from
AD patients than from healthy individuals
In the next series of experiments, we compared migration of
CD4þCCR4þ T cells and CD4þCXCR3þ T cells from AD
patients with those from healthy individuals (Figure 2a). We
observed a significantly higher chemotaxis index of
CD4þCCR4þ T cells in response to IL-13-stimulated HPKs
than to unstimulated cells with CD4þ T cells derived from
AD patients (chemotaxis index 1.7070.16, P¼0.01) as
well as with CD4þ T cells freshly isolated from healthy
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Figure 1. Chemotaxis of CD4þ T cells and preferential recruitment of
CD4þCCR4þ T cells in response to IL-13 stimulation of HPKs. HPKs were
treated with IL-13 (50 ng/ml) or IFN-g (10 ng/ml) for 24 hours. Purified CD4þ
T cells from healthy donors (n¼6) were added in the upper chamber and
IL-13-treated or -untreated HPKs in the lower chamber of the 24-well
transwell plate. Migration was performed for 3 hours at 371C in a humidified
environment. (a, b) For phenotype analysis, transmigrated CD4þ T cells were
stained for CXCR3 (Th1) and CCR4 (Th2) by using respective mAbs and
analyzed by flow cytometry. The numbers of cells transmigrated into the
lower chamber were counted, and absolute numbers of each subtype and
chemotaxis indices were calculated as described in Materials and Methods.
The gray lines depict mean values. NS¼ nonsignificant. **P-value o0.02,
and ***Po0.01.
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individuals (chemotaxis index 1.3470.11, P¼0.02). Inter-
estingly, as shown in Figure 2a, chemotaxis indices of
CD4þCCR4þ T cells from AD were significantly higher than
those from healthy individuals (P¼ 0.044). However, there
was no observable effect in migration of CD4þCXCR3þ
T cells derived from AD and healthy subjects towards IL-13-
stimulated HPKs as compared to unstimulated cells (Figure
2a). Moreover, Figure 2b depicts the representative experi-
ment of IL-13-induced transmigration of CD4þCXCR3þ and
CD4þCCR4þ T cells derived from AD (n¼6 for CXCR3,
n¼8 for CCR4) and healthy subjects (n¼ 6 for CXCR3, n¼ 8
for CCR4).
Recently, it has been shown that CCR4 could also be
expressed on Th0- or Th1-cells (Campbell et al., 1999). To
confirm that migrated CD4þ T cells are of Th2 origin, we
studied another Th2 marker, CRTH2. Initially, we investi-
gated the expression of CRTH2 in freshly isolated purified
CD4þ T cells and observed that AD patients have a higher
number of CD4þCRTH2þ T cells than that of healthy
individuals (Figure 3a), as previously observed by others
(Cosmi et al., 2000). Furthermore, we investigated the IL-13-
induced transmigration of CD4þCRTH2þ T cells of AD and
healthy individuals. Consistently, there was a significant
increase in the migration of absolute numbers of
CD4þCRTH2þ T cells in response to IL-13-stimulated HPKs
as compared with negative controls (P¼ 0.01, chemotaxis
index 1.570.15) in healthy individuals as well as in AD
patients (Figure 3b and c). In addition, Figure 3c depicts the
representative experiment of IL-13-induced transmigration of
CRTH2 cells derived from AD (n¼ 4) and healthy subjects
(n¼3).
Induction of CCL22 by IL-13 in HPKs attract CD4þCCR4þ
T cells
To confirm that the observed effect on migration of Th2-cells
was due to chemokine production by HPKs, we studied the
ability of HPKs to synthesize Th2-type C–C chemokines such
as CCL22 and CCL17 in vitro. HPKs were subjected to IL-13,
tumor necrosis factor-a (TNF-a), IL-1b, or a combination of
these cytokines for 4 hours. The mRNA levels of CCL22 and
CCL17 were then determined by real-time quantitative RT-
PCR. We used TNF-a and IL-1b stimulation, because HPKs
respond well to these cytokines, which are known to be
upregulated during inflammation. We showed that CCL22
mRNA was upregulated 2- to 8-fold by IL-13 stimulation
(Figure 4a). However, TNF-a, IL-1b or its combination with
IL-13 did not show synergistic effects within same time span
(data not shown). In contrast to CCL22, CCL17 was not
detected in IL-13-stimulated HPKs (Figure 4a).
CXCR3 CCR4 CXCR3 CCR40.5
1.0
1.5
2.0
2.5
3.0
*
Ch
em
ot
ax
is 
ind
ex
Healthy AD
7.39
16.82
Med IL-13 Med IL-13
Healthy AD
CX
CR
3
CCR4
a
b
9.76
22.33
25.36
17.4516.56
16.78
104
FL
1-
H
FL2-H
103
102
101
100 101102103104
104
FL
1-
H
FL2-H
103
102
101
100 101102103104
104
FL
1-
H
FL2-H
103
102
101
100 101102103104
104
FL
1-
H
FL2-H
103
102
101
100 101102103104
Figure 2. Higher migration of CD4þCCR4þ T cells derived from AD
patients than from healthy individuals towards IL-13-stimulated HPKs.
Purified CD4þ T cells either from healthy donors or AD patients were added
in the upper chamber and supernatants derived from IL-13-treated (50 ng/ml,
24 hours) or -untreated HPKs in the lower chamber of the 24-well transwell
plate. Migrations were performed for 3 hours at 371C in a humidified
environment. For phenotype analysis, transmigrated CD4þ T cells were
stained for CXCR3 (n¼6) and CCR4 (n¼8) by using respective mAbs and
analyzed by flow cytometry. The numbers of cells transmigrated into the
lower chamber were counted, and absolute numbers of each subtype and
chemotaxis indices were calculated as described in Materials and Methods
(a). Horizontal line shows mean values. Representative dotplots of an AD
patient and a healthy individual are shown (n¼ 6 for CXCR3, n¼8 for CCR4)
(b). The numbers in each quadrant are indicated in percentages of respective
subpopulations. *P-value o0.05.
1.68 4.42
Healthy AD
CR
TH
2
Med IL-13
H
ea
lth
y
AD
Forward scatter
CR
TH
2
Forward scatter
2.90 4.99
5.6 8.69
0
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
9,000 **
Ab
so
lu
te
 c
ou
nt
Med    IL-13
104
103
102
FL
2-
H
101
100
FSC-H
0 200 400 600 800 1000
104
103
102
FL
2-
H
101
100
FSC-H
0 200 400600 800 1000
104
103
102
FL
2-
H
101
100
FSC-H
0 200 400 600 800 1000
104
103
102
FL
2-
H
101
100
FSC-H
0 200 400 600 800 1000
104
103
102
FL
2-
H
101
100
FSC-H
0 200 400 600 800 1000
104
103
102
FL
2-
H
101
100
FSC-H
0 200 400 600 800 1000
a
c
b
Figure 3. Migration of CD4þCRTH2þ T cells in response to IL-13-
stimulated HPKs. (a) Freshly isolated CD4þ T cells either from peripheral
blood of healthy individuals or from AD patients were stained for CRTH2.
Representative dotplots of a healthy individual (n¼6) and an AD patient
(n¼6) are shown. (b) Purified CD4þ T cells either from healthy donors (n¼ 5)
or from AD patients (n¼3) were added in the upper chamber and IL-13-
treated or -untreated HPKs (50 ng/ml) in the lower chamber of the 24-well
transwell plate. Migration assays were performed for 3 hours at 371C in a
humidified environment. Transmigrated CD4þ T cells were stained for
CRTH2, the numbers of cells transmigrated into the lower chamber were
counted, and the absolute numbers of migrated CD4þCRTH2þ T cells and
chemotaxis indices were determined. (c) Representative dotplots of an AD
(n¼3) and a normal donor (n¼ 5) are shown. The numbers in each quadrant
are indicated in percentages of respective subpopulations. The gray lines
depict mean values. **P-value o0.02.
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The next question we addressed was whether CCL22
mRNA expression in unstimulated versus IL-13-stimulated
HPKs could be confirmed at the protein level. We measured
CCL22 in culture supernatants of HPKs collected 24 hours
after IL-13 (50 ng/ml) stimulation by specific ELISA (Figure
4b). HPKs produced pg/ml quantities of CCL22 (mean
78.4717.26, range 24.5–157 pg/ml, P¼ 0.0004) upon stimu-
lation with IL-13 as compared to unstimulated HPKs. We
further studied dose-dependent effects of IL-13 on CCL22
generation in HPKs. As depicted in Figure 4c, 10 ng/ml of IL-
13 was insufficient to induce CCL22 production in HPKs,
whereas 50 ng/ml of IL-13 could enhance the production
of CCL22 in HPKs significantly. Induction of CCL22 by IL-13
in HPKs may be responsible for the accumulation of
CD4þCCR4þ T cells; therefore, to prove this hypothesis,
we performed blocking experiments with neutralizing anti-
CCL22 antibody. As depicted in Figure 4d, CD4þCCR4þ T
cells migrated in response to IL-13-treated HPKs, whereas
pre-incubation with anti-CCL22 mAb significantly inhibited
the migration of CD4þCCR4þ T cells (80–90%). With this set
of experiments, we conclude that migration of these cells in
response to IL-13-stimulated HPKs was due to CCL22.
As all migrated CD4þ cells were not CD4þCCR4þ T
cells, we studied other T-cell chemoattractants, CCL2, CCL5,
and CCL20, after stimulation with IL-13 (50 ng/ml). At the
mRNA level, CCL2 was upregulated about 2- to 4-fold by IL-
13 stimulation (Figure 5a), but induction of CCL5 by IL-13
could not be detected in the same samples (Figure 5c).
Furthermore, we observed a little upregulation of CCL2
production upon stimulation with IL-13 as compared with
negative control (Figure 5b). In blocking experiments using
neutralizing anti-CCL2 mAb, we could not detect a consistent
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Figure 4. Induction of CCL22 by IL-13 in HPKs attract CD4þCCR4þ T cells. HPKs were stimulated with IL-13 (50 ng/ml) for 4 hours for RNA and with different
doses of IL-13 for 24 hours for protein measurement. Total RNA was isolated and subjected to real-time quantitative LightCycler RT-PCR. (a) Data are shown as
normalized ratio (CCL22/GAPDH), and a representative graph of the intensity of the fluorescence signal of the original data of CCL22 (n¼ 6), CCL17 (n¼ 3), and
housekeeping gene GAPDH with their corresponding melting curves are shown (n¼ 6) after IL-13 (50 ng/ml) stimulation as compared to un-stimulated cells
(n¼6). (b and c) In cell-free supernatants, CCL22 protein was measured by specific ELISA (n¼ 9). The gray lines depict mean values. (d) Supernatant from IL-13-
treated HPKs was preincubated for 2 hours with anti-CCL22 antibody before adding to the bottom chamber. Migration assays were performed with purified
CD4þ T cells derived from healthy donors for 3 hours at 371C. Transmigrated CD4þ T cells were stained for CCR4. Original data (un-processed) were
normalized to basal migration (un-stimulated HPKs, dotted line) for each experiment and shown as chemotaxis index. **P-value o0.02 and ***Po0.01.
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inhibition of CD4þ T-cell migration. Furthermore, there
was no induction of CCL20 in IL-13- or IL-4-stimulated
HPKs alone or in combination with other pro-inflammatory
cytokines (data not shown).
IL-13-positive cells have been shown to be present in the
chronic phase of AD patients where IFN-g, a Th-1 signature
cytokine, dominates (Hamid et al., 1996). Therefore, in the
next series of experiments, we investigated the effect of IL-13
on IFN-g-induced chemokines synthesis in HPKs. As shown
in Figure 6, IL-13 and IL-4 markedly enhanced the IFN-g-
induced CCL5 and CCL2. However, neither IL-13 nor IL-4
could modulate the IFN-g-induced CCL22 in HPKs.
DISCUSSION
HPKs play a pivotal role in skin inflammation through the
regulated expression of chemokines attracting various leuko-
cyte subsets, including monocytes, dendritic cells, and
T-lymphocytes. Several evidences confirm a T-cell-mediated
pathogenesis for inflammatory skin diseases such as AD,
psoriasis, and allergic-contact dermatitis. Accumulation of T
cells in the skin compartment from peripheral blood is highly
dependent on chemokines and expression of chemokine
receptors. Our study demonstrates that IL-13-stimulated HPKs
express CCL22, which preferentially attract CD4þCCR4þ T
cells. Furthermore, CD4þCCR4þ T cells from AD patients
showed higher chemotactic indices towards IL-13-stimulated
HPKs than those from healthy individuals.
We initially used transmigration assay to confirm prefer-
ential migration of Th2-cells toward IL-13-stimulated HPKs.
Previously, IL-13 has been shown to be relevant in
the recruitment of T cells and eosinophils to the inflammatory
site by upregulating various adhesion molecules, and
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chemokines (Li et al., 2000; Lukacs, 2000). In AD patients,
higher numbers of IL-13-positive cells appear to be present in
acute lesions than in chronic lesions as shown on the mRNA
level previously (Hamid et al., 1996). Recently, it has been
shown that IL-13 is a major inducer of Th2 milieu in the
cutaneous microenvironment, being required independent of
IL-4 (Herrick et al., 2003). This fact, in combination with the
relative abundance of IL-13 over IL-4 in subacute and chronic
AD, emphasizes the potentially important role of IL-13 in the
pathogenesis of AD (Tazawa et al., 2004).
To investigate the phenotype of migrated CD4þ T cells
(Th1/Th2), we used CXCR3 and CCR4 surface markers as the
inflammatory cells express different chemokine receptors
depending on their differentiation and activation state. In
particular, Th1-cells express high levels of CCR5 and CXCR3,
whereas Th2-cells express high CCR4 and CCR8 levels
(Yamamoto et al., 2000; Gombert et al., 2005). We observed
higher chemotactic indices of CD4þCCR4þ T-cell migration
in AD as compared to healthy individuals. It has been shown
that CCR4 plays an important role in the migration of Th2-
cells from peripheral blood into the inflamed skin (Reiss et al.,
2001). Our results point to the fact that the higher rate of
migration of CD4þCCR4þ T cells in AD patients may not be
only due to a higher frequency of CCR4þ cells in AD patients
(Nakatani et al., 2001) but also because of higher migratory
capacity of CCR4þ cells from AD than healthy individuals.
To further confirm that migrated CD4þCCR4þ T cells are
of Th2 phenotype, we used another Th2 marker, CRTH2, that
has been shown to be expressed selectively on a subpopula-
tion of Th2-cells but not on Th0- and Th1-cells (Cosmi
et al., 2000). Consistently, we observed higher frequency of
CRTH2-positive cells in AD patients than in healthy
individuals. Moreover, we observed higher migration of
CRTH2 cells towards IL-13-stimulated HPKs in AD as well as
in healthy individuals.
For CD4þCXCR3þ T cells, we observed almost the same
or a marginal increase of migration towards IL-13-stimulated
HPKs as compared to unstimulated cells. Moreover, no
significant difference could be observed in AD versus healthy
individuals. Recently, it has been shown that IL-4 upregulates
the IFN-g- or TNF-a-induced CXCR3 agonist expression
(Albanesi et al., 2000). As the cytokine micromilieu and
timing of signal are important for the induction of several
genes (Wittmann et al., 1999), this may explain why we have
observed preferential enrichment of CD4þCCR4þ T cells
towards IL-13-stimulated HPKs (no pre-incubation with TNF-a
or IFN-g); however, no significant effect on migration of
CD4þCXCR3þ T cells.
To understand the mechanism of migration of Th2-cells,
we have evaluated the ability of HPKs to newly synthesize
and release CCL22 and CCL17. Results of in vitro experi-
ments demonstrated that HPKs were capable of generating
significant quantities of CCL22 protein, but induction of
CCL17 could not be observed in the same experimental
settings. Recently, in vivo presence of CCL22-positive cells in
skin lesions of AD in both the epidermis (keratinocytes)
(Horikawa et al., 2002) and the dermis (mature DCs)
(Vulcano et al., 2001) has been demonstrated. The in vitro
secretion of CCL22 by IL-13-stimulated HPKs in this study
strongly suggests that CCL22 expressed by HPKs may
function to recruit CCR4þ lymphocytes into inflamed
epidermis. In monocytes, IL-4 and IL-13 have been reported
to augment CCL22 expression (Bonecchi et al., 1998b),
whereas in HaCaT (spontaneously immortalized human
keratinocytes) cells, IL-13 has been shown to downregulate
the CCL22 release (Fujii-Maeda et al., 2004). HaCaTs are a
human keratinocytes cell line, which we have not used in this
study. Here, we used HPKs, hence differences in the result
could be because of differences between cell lines and
primary cells. Recently, differences in the NF-kb pathway
have also been shown between HaCaTs and HPKs (Muller
et al., 2003). In our study, IL-13 itself exerted significant
effects on HPKs, but TNF-a or IL-1b did not show synergy
with IL-13 in the induction of CCL22, unlike in bronchial
epithelial cells (Sekiya et al., 2000).
Several recent studies demonstrated that infiltration of
IFN-g-positive cells into the epidermis leads to apoptosis of
keratinocytes, and thus contributing to the skin inflammation
in AD (Klunker et al., 2003). Our study demonstrates that
CD4þCXCR3þ and CD4þCCR4þ T cells migrate in
response to IFN-g-treated HPKs. IFN-g induced CCL22
production in HPKs (our own observation) and in HaCaT
keratinocytes (Fujii-Maeda et al., 2004). These results were
rather surprising, because CCL22 and CCL17 are usually
considered to play a role in Th2-dominated disorders such as
allergic responses, but not in Th1-mediated disorders. IFN-g
inhibits the development of Th2-cells, antagonizes Th2-
dependent effects such as inhibition of signal transducer and
activator of transcription 6 and its downstream genes, and
downregulates CCL22 in monocytes (Bonecchi et al., 1998b;
Heller et al., 2004). Therefore, it appears that IFN-gmay exert
dichotomous effects on the pathogenesis of AD. This might
be an important clue in understanding the pathogenesis of the
chronic phase of AD where a mixed (Th1 and Th2) cytokine
milieu has been observed.
Besides CD4þ -lymphocytes, CCL2 potently attracts
monocytes and dendritic cells. In this study, we could
observe a little induction of CCL2 in HPKs after IL-13
stimulation. The slight induction of CCL2 by IL-13 alone may
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Figure 6. IL-13 enhances IFN-c-induced chemokines CCL2 and CCL5 in
HPKs. HPKs were stimulated with IFN-g (10 ng/ml) alone and in combination
with IL-13 (50 ng/ml) or IL-4 (50 ng/ml) for 24 hours. In cell-free supernatants,
CCL2, CCL5, and CCL22 at protein levels were measured by specific ELISA
(n¼4). Data are expressed as mean pg/ml7standard error of mean. *P-value
o0.05, and **Po0.02 when compared with IFN-g-stimulated cells.
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not account for biologically important effects; however, in
concert with IFN-g, we observed a marked induction of CCL2
as well as CCL5 in HPKs. This suggests that CCL2 and CCL5
may contribute to the mixed Th1/Th2 infiltrate that char-
acterizes the chronic phase of AD. Basal keratinocytes
strongly express CCL2 in patients with AD (Giustizieri
et al., 2001). IL-4 has also been shown to induce marginal
increase in IFN-g-induced CCL2 in oral keratinocytes (Li
et al., 2000). Therefore, it is another insight of the potential
role of IL-13 in amplifying the inflammatory response at the
target site by recruiting various leukocytes, thereby facilitat-
ing the chronification of inflammatory eczematous response.
Although it is well established that multiple C–C chemo-
kines are produced by HPKs, there were remarkable
variations within the HPKs isolated and cultured from
different healthy individuals in the induction level of CCL22
and CCL2. These probably represent heterogeneity in the
population with respect to genetic background. In agreement
to our results, previous study also observed the donor-
dependent variability in the expression of CCR-3 in HPKs
(Petering et al., 2001).
Taken together, our results indicate the mechanisms of
regulation of epithelial chemokine production and thereby
amplifying the inflammatory response in the skin. We have
demonstrated that IL-13-activated HPKs represent an im-
portant source of the chemokine CCL22 and preferentially
enrich Th2-cells as observed in the migration assays. More-
over, IL-13 in concert with IFN-g induces high amounts of
CCL2 and CCL5 in HPKs. With the recent evidences, we
conclude that IL-13 plays a dichotomous role in the
pathogenesis of AD by enriching Th2 cells in acute phase
and a mixed lymphocytes population in chronic phases of
allergic skin inflammation.
MATERIALS AND METHODS
Cytokines and reagents
All cytokines were used as purified recombinant human prepara-
tions. Human IL-13 was purchased from PromoCell GmbH (Heidel-
berg, Germany); IFN-g from ImmunoTools (Friesoythe, Germany);
and IL-4 from R&D Systems (Wiesbaden, Germany).
Cell isolation and culture
Peripheral blood mononuclear cells either from healthy individuals
or AD patients were separated by Ficoll–Hypaque density-gradient
centrifugation. AD patients suffered from the extrinsic form of the
disease. SCORing Atopic Dermatitis were in the range of 12–35.
At the time point blood samples were taken, none of the patients
received systemic medication, but most of them used local steroids
(class II–III). The study was approved by the ethics committee of the
Hannover Medical School and was conducted according to the
Declaration of Helsinki Principles. All participants gave their written
informed consent. Monocytes were depleted by adherence and
CD4þ T cells were purified from nonadherent cells by using a
negative selection kit (Miltenyi Biotech, Bergisch Gladbach,
Germany). Purity of the resulting CD4þ T cells was consis-
tently X95%, as verified by flow cytometry analysis of CD4þ
T cells (mouse anti-human CD4 mAb; Beckman-Coulter, Krefeld,
Germany). After separation, cells were resuspended in Iscove
medium (Biochrom, Berlin, Germany) supplemented with 4%
human AB serum.
Primary cultures of normal human keratinocytes were prepared
from foreskin of children undergoing surgery as described previously
(Wittmann et al., 2005). In brief, the single-cell suspension of
keratinocytes was cultured in serum-free keratinocytes growth
medium (Keratinocyte Growth Medium 2 Kit; PromoCell GmbH,
Heidelberg, Germany). All cell cultures were incubated in a
humidified atmosphere containing 5% CO2 at 371C and were used
at the passage 2–5. Hydrocortisone-free medium was used for all
experiments. The purity of HPKs was verified by the expression of
the epithelial marker cytokeratin (anti-human cytokeratin antibody,
clone: MNF-116; DakoCytomation, Hamburg, Germany). All cells
(more than 95%) were found to be uniformly positive for cytokeratin.
Flow cytometric analysis of intracellular and membrane
molecules
Expression of surface antigens was assessed as described previously
(Wittmann et al., 2002). The following phycoerythrin- or FITC-
labelled mAb were used: CXCR3 (clone 49801; R&D Systems,
Wiesbaden, Heidelberg, Germany), CCR4, (clone 1G1; BD Bios-
ciences), and CRTH2 (clone BM 16; Miltenyi Biotech, Bergisch
Gladbach, Germany). Cytokeratin (DakoCytomation) was detected
by intracellular staining using the Cytofix/Cytoperm kit (BD
Biosciences). Stained cells were measured by flow cytometry
(FACSCalibur) and analyzed using CELLQuestProTM software (BD
Biosciences).
Migration assay
Purified CD4þ T cells (1 106/150 ml) from either healthy or AD
donors were added to the top chamber of 5-mm pore size
polycarbonate 24-well Transwell culture insert (Costar, NY) contain-
ing undiluted supernatants from either unstimulated or IL-13-
stimulated HPKs (about 70% confluent) in the bottom chamber.
Migration assays were carried out for 3 hours at 371C in a CO2
incubator. The numbers of migrated cells were counted by BD
Truecount tubes (BD Biosciences) and absolute numbers were
determined according to the manufacturer’s instructions. To
determine the Th1 or Th2 phenotype, migrated cells were stained
with fluorochrome-conjugated CXCR3, CCR4, or CRTH2 mAbs, and
the number of cells migrated were calculated with the following
formula (total number of cells migrated% age of subtype of cells/
100). Chemotaxis indices were calculated as the ratio of the absolute
numbers of cells migrated towards stimulated cells divided by the
numbers of cells migrated towards unstimulated HPKs (negative
control). For the blocking experiments, supernatants derived from IL-
13-activated HPKs were pre-incubated with 10 mg/ml anti-human
CCL22 antibody (clone 57226.11; R&D Systems) and anti-human
CCL2 antibody (clone 24822; R&D Systems) for 2 hours, before the
setup of chemotaxis assay.
mRNA isolation, reverse transcription, and LightCycler PCR
mRNA isolation and reverse transcription were performed as
described previously (Wittmann et al., 2004) by using the ‘‘High
Pure mRNA Isolation Kit’’ (Roche Molecular Biochemicals, Man-
nheim, Germany) and ‘‘First Strand cDNA Synthesis Kit’’ (MBI
Fermentas, St Leon-Rot, Germany). The quantitative real-time PCR
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was performed on a LightCycler (Roche Molecular Biochemicals) by
using ‘‘LightCyclers FastStart DNA MasterPLUSSYBR Green I’’
(Roche Molecular Biochemicals). CCL22, CCL17, CCL2, CCL5,
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were run
in a touchdown PCR program (target temperature, 681C; secondary
target temperature, 581C; step size, 0.5; and step delay, 1). The
following primers were used for PCR amplification: CCL22 sense –
50-ACC TAT GTG TCG TGT CT-30 and CCL22 antisense – 50-CGC
TAC GCT ACC ACA G-30; CCL17 sense – 50-ATG GCC CCA CTG
AAG ATG CT-30 and CCL17 antisense –50-TGA ACA CCA ACG GTG
GAG GT-30; CCL2 sense – 50-AGA TGC AAT CAA TGC CC-30 and
CCL2 antisense – 50-TGG AAT CCT GAA CCC AC-30; CCL5 sense –
50-CCA TGA AGG TCT CCG C-30 and CCL5 antisense – 50-CAT CCT
AGC TCA TCT CCA A-30; and GAPDH sense – 50-CCA CAT CGC
TCA GAC-30 and GAPDH antisense – 50-GGC AAC AAT ATC CAC
TTT ACC AGA GT-30. For quantitative analysis, standard curves for
CCL22, CCL17, CCL2, and CCL5 were created covering a range of
six orders of magnitude by dilution series (dilutions from these
standard curves were used as calibrators in further experiments).
These standard curves describing the PCR efficiencies of the target
CCL22, CCL17, CCL2, or CCL5 and the reference gene (GAPDH)
allow an efficiency-corrected quantification using the ‘‘Relative
Quantification Software’’ (Roche Molecular Biochemicals). The
calibrator-normalized relative quantification results in a target
concentration expressed relative to the concentration of the
reference gene in the same sample material.
Quantification of chemokines
In all experiments, HPKs were grown in a 24-well plate (Nunc Inc.,
Wiesbaden, Germany) in a 60–90% cell density in 0.5 ml of
keratinocytes medium. After stimulation with appropriate cytokines
for 24–48 hours, supernatants were collected. Concentrations of
CCL22, CCL5, CCL20, and CCL2 in the cell-free supernatants of
cytokine(s)-stimulated HPKs were measured by DuoSet ELISA of
CCL22, CCL5, and CCL20 (R&D Systems, Wiesbaden, Germany)
and CCL2 ELISA development kit (Peprotech, Germany) according to
the manufacturer’s instructions.
Statistical analysis
Comparative data were analyzed by using the Mann–Whitney rank-
sum test (Figure 2), t-test (Figure 6), and paired t-test (paired data
are depicted). The software used to perform the statistical analysis
was Prism 3.03. Mean values7standard error of mean are depicted.
In the figures, *stands for a P-value o0.05, **Po0.02, and
***Po0.01.
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